HELICOS BIOSCIENCES CORP 8-K 2007
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Amendment No. 1)
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 30, 2007
HELICOS BIOSCIENCES CORPORATION
(Exact Name of Registrant as Specified in Charter)
(Registrants telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
On November 5, 2007, Helicos BioSciences Corporation (Helicos or the Company) filed a Current Report on Form 8K under Item 5.02 (the Original Filing) to report the appointment of Ronald A. Lowy to its Board of Directors. Because Mr. Lowy had not been appointed to serve on any committee of the board at the time the Form 8K was filed, disclosure of the committees of the board on which he would serve was not included in accordance with Instruction No. 2 of the Instructions to Item 5.02. This Form 8K/A is filed as an amendment to the Original Filing.
(d) The Board of Directors of the Company elected Ronald A. Lowy to serve as a member of the Companys Board of Directors effective as of October 30, 2007 and on November 30, 2007 the Board of Directors appointed Mr. Lowy to serve on the Audit Committee. In connection with Mr. Lowys appointment, Steven St. Peter elected to resign from the Audit Committee. Mr. Lowy will serve as a Class III Director whose initial term will expire at the annual meeting of stockholders held in 2010. Since April 2007, Mr. Lowy has served as a self-employed consultant. Mr. Lowy was the President and CEO of Fisher BioSciences from November 2004 until April 2007. Previously, Mr. Lowy was President, Global Connectivity Solutions of ADC Telecommunications in 2004 and President and Chief Operating Officer of Krone Group from 2001 to 2004. There are no arrangements between Mr. Lowy and any other persons pursuant to which Mr. Lowy was selected as a director. There are no transactions, or proposed transactions, to which the Company is or was to be a party and in which Mr. Lowy had a direct or indirect material interest that are required to be disclosed under Item 404(a) of Regulation S-K. A copy of the press release announcing Mr. Lowys election is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
* Previously Filed
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INDEX OF EXHIBITS
* Previously Filed